1 completed, 1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow eXIthera Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients EP-7041 Injection - Thrombopenia, Covid19 | Phase 2 | Withdrawn | eXIthera Pharmaceuticals | 2023-10-01 | 2023-10-05 | |
| Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects EP=7041, Placebo - Arthroplasty, Replacement, Knee | Phase 1 | Completed | eXIthera Pharmaceuticals | 80 | 2016-07-01 | 2017-05-31 |
COVID-19 (1) · Embolism and Thrombosis (1) · Thrombocytopenia (1) · Thromboembolism (1) · Venous Thromboembolism (1)
Australia (1) · United States (1)
Charles V. Pollack, Jr.,, MA, MD (1) · Sepehr Shakib, MD (1)